

Chad V Pecot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4909195/publications.pdf>

Version: 2024-02-01

58
papers

5,401
citations

126907

33
h-index

161849

54
g-index

60
all docs

60
docs citations

60
times ranked

12760
citing authors

#	ARTICLE	IF	CITATIONS
1	RNA interference in the clinic: challenges and future directions. <i>Nature Reviews Cancer</i> , 2011, 11, 59-67.	28.4	729
2	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	27.0	651
3	Tumour angiogenesis regulation by the miR-200 family. <i>Nature Communications</i> , 2013, 4, 2427.	12.8	363
4	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. <i>Cancer Cell</i> , 2013, 23, 186-199.	16.8	340
5	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. <i>Cancer Cell</i> , 2014, 26, 77-91.	16.8	252
6	Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location. <i>Nano Letters</i> , 2017, 17, 2879-2886.	9.1	199
7	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. <i>Nature Communications</i> , 2014, 5, 5203.	12.8	195
8	Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles. <i>Neoplasia</i> , 2011, 13, 309-IN8.	5.3	191
9	A Novel Platform for Detection of CK+ and CK ⁻ CTCs. <i>Cancer Discovery</i> , 2011, 1, 580-586.	9.4	189
10	Role of Focal Adhesion Kinase in Regulating YB ¹ -Mediated Paclitaxel Resistance in Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1485-1495.	6.3	151
11	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. <i>Cancer Discovery</i> , 2013, 3, 1302-1315.	9.4	140
12	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	7.0	122
13	KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. <i>Cancer Cell</i> , 2018, 34, 807-822.e7.	16.8	112
14	2 ^o -OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014, 5, 3459.	12.8	103
15	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	102
16	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	8.2	101
17	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016, 7, 11169.	12.8	100
18	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015, 28, 610-622.	16.8	94

#	ARTICLE	IF	CITATIONS
19	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
20	Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2876-2885.	4.1	77
21	Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 602-610.	7.0	72
22	Factor XIII α 2-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. <i>Nature Communications</i> , 2018, 9, 1988.	12.8	69
23	Endothelial miR-30c suppresses tumor growth via inhibition of TGF- β 2-induced Serpine1. <i>Journal of Clinical Investigation</i> , 2019, 129, 1654-1670.	8.2	60
24	Notch3 Pathway Alterations in Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3282-3293.	0.9	59
25	Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 786-792.	2.5	55
26	Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. <i>Nature Communications</i> , 2019, 10, 4192.	12.8	52
27	miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 25930-25948.	1.8	49
28	High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. <i>Science Advances</i> , 2020, 6, eaba5542.	10.3	48
29	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. <i>Cancer Cell</i> , 2014, 26, 863-879.	16.8	46
30	Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 4114-4121.	7.0	45
31	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. <i>Cell Reports</i> , 2014, 7, 488-500.	6.4	43
32	Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	43
33	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, e5-e11.	2.6	39
34	Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. <i>Nanoscale Horizons</i> , 2021, 6, 319-329.	8.0	39
35	Targeting Src and Tubulin in Mucinous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 6532-6543.	7.0	38
36	Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer. <i>ACS Nano</i> , 2020, 14, 7200-7215.	14.6	38

#	ARTICLE	IF	CITATIONS
37	Cancer's got nerve: Schwann cells drive perineural invasion. <i>Journal of Clinical Investigation</i> , 2016, 126, 1242-1244.	8.2	37
38	Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. , 2022, 10, e003897.		27
39	Cross-talk between EphA2 and BRAF/CRaf Is a Key Determinant of Response to Dasatinib. <i>Clinical Cancer Research</i> , 2014, 20, 1846-1855.	7.0	25
40	Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2018, 9, 307.	3.5	25
41	Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. <i>Nature Communications</i> , 2022, 13, 2154.	12.8	25
42	Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100126.	1.7	24
43	A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. <i>Cancer Research</i> , 2020, 80, 4972-4985.	0.9	23
44	Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. <i>Oncogene</i> , 2019, 38, 5191-5210.	5.9	19
45	Targeting Epigenetics in Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038000.	6.2	18
46	A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. <i>Breast Cancer Research</i> , 2018, 20, 45.	5.0	15
47	Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. <i>Cancer</i> , 2020, 126, 1060-1067.	4.1	13
48	Coronin 1C inhibits melanoma metastasis through regulation of MT1-MMP-containing extracellular vesicle secretion. <i>Scientific Reports</i> , 2020, 10, 11958.	3.3	12
49	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. <i>Molecular Systems Biology</i> , 2015, 11, 842.	7.2	10
50	Incidence and clinical relevance of non-small cell lung cancer lymph node micro-metastasis detected by staging endobronchial ultrasound-guided transbronchial needle aspiration. <i>Journal of Thoracic Disease</i> , 2019, 11, 3650-3658.	1.4	9
51	Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 703-712.	4.9	7
52	RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. <i>Lung Cancer</i> , 2021, 153, 90-98.	2.0	6
53	Preparation and Characterization of Poly(2-oxazoline) Micelles for the Solubilization and Delivery of Water Insoluble Drugs. <i>Bio-protocol</i> , 2021, 11, e3959.	0.4	3
54	Diagnostic Characteristics of a Serum Biomarker in Patients With Positron Emission Tomography Scans. <i>Annals of Thoracic Surgery</i> , 2010, 89, 1724-1729.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 666691.	2.8	2
56	Incorporating Pericytes into an Endothelial Cell Bead Sprouting Assay. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	1
57	Immunotherapy combinations emerging in non-small-cell lung cancer. <i>Immunotherapy</i> , 2018, 10, 627-629.	2.0	0
58	Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents. <i>Bio-protocol</i> , 2021, 11, e3953.	0.4	0